ArticleDiscover oncology2025
Molecular mechanisms of RACK1-driven metastasis in pancreatic ductal adenocarcinoma revealed by single-cell RNA sequencing.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with significant cellular heterogeneity, which poses a significant challenge for treatment. We integrated three single-cell RNA sequencing (scRNA-seq) datasets to construct an expression matrix, identify cell types, and assess copy number variation (CNV) scores, with a particular focus on ductal cells. Our study found that ductal cells are the primary source of malignant cells in PDAC and identified a high-malignancy subtype—ductal cell-3—where RACK1 was the most significantly differentially expressed gene. Through the analysis of public and clinical data, along with RT-qPCR and immunohistochemistry validation, we confirmed the high expression of RACK1 in PDAC tumors, which correlated with lymph node metastasis, clinical staging, histological differentiation, and prognosis. Further investigation revealed that RACK1 promotes PDAC cell proliferation, migration, and invasion. Sequencing analysis indicated that RACK1 inhibits the FOXO signaling pathway, promotes epithelial-mesenchymal transition (EMT), and facilitates the progression and metastasis of PDAC. This study provides new insights into the role of RACK1 in PDAC and its underlying mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.